Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases
Pediatric Pulmonology · 2025-04 · 60 (4)
DOI: 10.1002/ppul.71073 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Pulmonology, 2025-04. Verfasst von Laura A Voss und 23 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Genetic Testing, Lung Diseases, Interstitial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, Financial support was provided by the National Institutes of Health, the Children's Discovery Institute at St. Louis Children's Hospital, and the Children's Ho….
Abstract (Originalsprache)
Introduction
Childhood interstitial and diffuse lung diseases (chILD) comprise a diverse group of rare disorders. Identifying the underlying cause is crucial for treatment, prognosis, and estimating recurrence risk. The objective of this study was to assess the utilization of genetic testing for subjects enrolled in the United States National Registry for ChILD, a multicenter observational study.
Methods
Genetic data from participating sites were reviewed and analyzed in relationship to clinical characteristics.
Results
Of 609 children enrolled from 22 centers, genetic testing was performed for 55.5% ( n = 338). Genetic testing results were positive (diagnostic) for 22.8% ( n = 77), negative for 60.7% ( n = 205), and uncertain for 16.6% ( n = 56). Most testing was performed through gene panels (55.9%), followed by exome sequencing (ES) or whole genome sequencing (WGS) (26.9%), single gene testing (24.6%), and/or chromosomal microarray (11.8%). For participants with positive (diagnostic) genetic testing results, the majority were diagnosed through gene panel (33.8%; n = 26) or single gene testing (32.5%; n = 25). The most common diagnosis confirmed by genetic testing was SFTPC ‐associated surfactant metabolism dysfunction. Of the 59 subjects with unclassified ILD, only 22% ( n = 13) had undergone ES or WGS, 61% ( n = 36) had received panel testing, and 27% ( n = 16) did not have any genetic testing reported.
Conclusion
The utilization of genetic testing has been variable in infants and children enrolled in the ChILD Registry. Additional efforts are needed to develop genetic testing recommendations for children with suspected ILD. Furthermore, there is opportunity for broader utilization of ES/WGS and genetic discovery for children with lung disease of unclear etiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatrics, Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.
- Pediatrics, Division of Pediatric Pulmonary Medicine, University of Missouri School of Medicine and Children's Hospital, Columbia, Missouri, USA.
- Division of Newborn Medicine, Edward Mallinckrodt Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, USA.
- Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Pediatrics, Section of Pediatric Pulmonary and Sleep Medicine, University of Colorado Denver, Aurora, Colorado, USA.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- Financial support was provided by the National Institutes of Health, the Children's Discovery Institute at St. Louis Children's Hospital, and the Children's Ho…
- National Institutes of Health
Zitieren
APA
Voss, L. A., Nevel, R. J., Wambach, J. A., Nogee, L. M., Deterding, R. R., Casey, A. M., O'Connor, M. G., Craven, D. I., Taylor, J. B., Deutsch, G. H., Tam-Williams, J. B., Steffes, L. C., Brennan, S. K., Santiago, M. T., Sadreameli, S. C., Heras, A. F., Powers, M. R., Popova, A. P., Bansal, M., …, & ChILD Registry Collaborative (2025). Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases. Pediatric Pulmonology, 60(4). https://doi.org/10.1002/ppul.71073
Vancouver
Voss LA, Nevel RJ, Wambach JA, Nogee LM, Deterding RR, Casey AM, et al. Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases. Pediatric Pulmonology. 2025;60(4). doi:10.1002/ppul.71073
BibTeX
@article{Voss2025,
author = {Voss, Laura A and Nevel, Rebekah J and Wambach, Jennifer A and Nogee, Lawrence M and Deterding, Robin R and Casey, Alicia M and O'Connor, Michael G and Craven, Daniel I and Taylor, Jane B and Deutsch, Gail H and Tam-Williams, Jade B and Steffes, Lea C and Brennan, Steven K and Santiago, Maria T and Sadreameli, Sara C and Heras, Andrea F and Powers, Michael R and Popova, Antonia P and Bansal, Manvi and Hamvas, Aaron and Gower, William A and Urrego, Fernando and Young, Lisa R and ChILD Registry Collaborative, ChILD Registry Collaborative},
title = {Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases},
journal = {Pediatric Pulmonology},
year = {2025},
volume = {60},
number = {4},
doi = {10.1002/ppul.71073}
}
EUVIMED